Agenus Inc. Common Stock (AGEN) Stock
NASDAQ · AGEN
8.56
Fundamentals
Market cap
$385.68M
Price / Earnings ratio
4.2x
Price / Sales ratio
2.9x
Price / Book ratio
-1.9x
Return on assets
31.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Business Wire
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
NeutralAGENSeptember 10, 2026
Business WireNeutral
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
AGEN

Business Wire
Agenus to Participate in Upcoming September Investor Conferences
NeutralAGENAugust 31, 2026
Business WireNeutral
Agenus to Participate in Upcoming September Investor Conferences
AGEN

Business Wire
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
NeutralAGENAugust 28, 2026
Business WireNeutral
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
AGEN

Business Wire
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
NeutralAGENAugust 26, 2026
Business WireNeutral
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
AGEN
Technicals
OscillatorsStrong Buy5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy3
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
137M90M45M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
606M400M200M0
Revenue to Profit
2025$114.2M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$115000.0
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Business Wire
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
NeutralAGENSeptember 10, 2026
Business WireNeutral
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
AGEN

Business Wire
Agenus to Participate in Upcoming September Investor Conferences
NeutralAGENAugust 31, 2026
Business WireNeutral
Agenus to Participate in Upcoming September Investor Conferences
AGEN

Business Wire
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
NeutralAGENAugust 28, 2026
Business WireNeutral
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
AGEN

Business Wire
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
NeutralAGENAugust 26, 2026
Business WireNeutral
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
AGEN

Zacks Investment Research
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
NeutralAGENAugust 7, 2026
Zacks Investment ResearchNeutral
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
AGEN

Business Wire
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
NeutralAGENAugust 6, 2026
Business WireNeutral
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
AGEN

Zacks Investment Research
Agenus (AGEN) Earnings Expected to Grow: Should You Buy?
NeutralAGENJuly 30, 2026
Zacks Investment ResearchNeutral
Agenus (AGEN) Earnings Expected to Grow: Should You Buy?
AGEN

Business Wire
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
NeutralAGENJuly 28, 2026
Business WireNeutral
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
AGEN

Zacks Investment Research
Do Options Traders Know Something About Agenus Stock We Don't?
NeutralAGENJuly 23, 2026
Zacks Investment ResearchNeutral
Do Options Traders Know Something About Agenus Stock We Don't?
AGEN

Business Wire
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
NeutralAGENJuly 17, 2026
Business WireNeutral
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
AGEN
About Agenus Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees81
CEODr. Garo H. Armen Ph.D.
IPO DateFeb 4, 2000
HeadquartersLexington, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Garo H. Armen Ph.D. | Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman | 1953 |
| Dr. Steven J. O'Day M.D., Ph.D. | Chief Medical Officer | 1961 |
| Dr. Jennifer S. Buell Ph.D. | Director and President & CEO of MiNK Therapeutics | 1975 |
| Craig Winter | Chief Information Officer | — |
| Mr. Zack Armen | Vice President of Investor Relations & Corporate Development | — |
| Ms. Stefanie Perna-Nacar | Chief Communications & Government Relations Officer | — |
| Ms. Tracy Mazza Clemente | Chief People Officer | — |
| Dr. Todd Jude Yancey M.D. | Member of Advisory Board & Chief Strategic Advisor | — |
| Dr. Robin G. Taylor M.B.A., Ph.D. | Chief Commercial Officer | — |
| Dr. Kamel Djazouli M.D. | Head of Medical Affairs | — |
Fundamentals
Valuation
Market cap$385.68M
Price-to-sales ratio2.88
Price-to-book value-1.92
Price-earnings ratio4.20
Return on Equity-23.00%
Return on Sales98.00%
Return on Assets31.00%
PEG ratio1.44
Earnings Per Share
Earnings Per Share$2.65
Income Statement
Average volume919,136
EBITDA$129.13M
1 year high (52w)$8.85
1 year low (52w)$2.71
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Buy5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
3 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$26.33
Est return
208.35%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.2 | -27.8 | -28.2 | +8.1 | ||||||||
| 2022 | -20.5 | -0.4 | -5.0 | -28.0 | -13.9 | +21.2 | +31.6 | +8.9 | -24.9 | +20.1 | +7.6 | -9.1 |
| 2023 | +8.8 | -20.5 | -21.6 | -3.8 | +3.3 | +0.6 | +0.0 | -5.5 | -18.7 | -23.8 | -6.4 | +5.8 |
| 2024 | -16.6 | +5.5 | -12.1 | +3.1 | +18.3 | -1.3 | -63.8 | -13.7 | +10.7 | -17.6 | -15.6 | -26.5 |
| 2025 | +23.0 | -18.8 | -40.6 | +80.6 | +19.9 | +10.7 | +14.0 | -22.0 | -7.5 | +1.8 | +14.9 | -27.3 |
| 2026 | -12.1 | +16.4 | +0.0 | +15.0 | -8.9 | -12.1 | +119.9 | -2.7 | +6.9 |



